Omicron News and Research

RSS

What is the effect of the Omicron variant on olfaction?

A new study discusses the effect of the Omicron variant of the virus on the olfactory system in humans.

15 Sep 2022

COVID-19's future is uncertain as infections increase and tracking decreases

Researchers review how the SARS-CoV-2 genome has changed throughout the COVID-19 pandemic.

14 Sep 2022

High levels of mucosal antibodies in the airways reduce the risk of omicron infection

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three doses of the SARS-CoV-2 vaccine.

14 Sep 2022

Customized bivalent mRNA COVID boosters protect against BA.5 Omicron variant

In a recent study posted to the bioRxiv* pre-print server, researchers from Washington University School of Medicine, Moderna, Inc, and the U.S. National Institutes of Health tested two bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines based on the messenger ribonucleic acid (mRNA) platform.

14 Sep 2022

COVID-19 risk substantially reduced in seniors who receive 4th mRNA booster

In a recent study published in the Annals of Internal Medicine, researchers in Singapore estimated the effectiveness of the second booster (fourth dose) vaccination with messenger ribonucleic acid (mRNA) vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections with the SARS-CoV-2 Omicron variant and associated hospitalizations with among individuals aged ≥80 years.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

Forecasting COVID-19 surges based on SARS-CoV-2 mutation surveillance

Researchers predicted surges in SARS-CoV-2 infections based on alterations in SARS-CoV-2 mutations.

13 Sep 2022

SARS-CoV-2 breakthrough infection in vaccinated individuals induces virus-specific nasal T cells of broad specificity

Long-lasting immune cells that specifically recognize the SARS-CoV-2 virus were found in the noses of people who were infected following vaccination.

12 Sep 2022

Vaccines that induce mucosal immunity against SARS-CoV-2 are needed

In a recent study posted to the medRxiv* preprint server, researchers in the United Kingdom studied assessed plasma and nasal antibody (Ab) responses induced after a year of coronavirus disease 2019 (COVID-19)-associated hospitalization and the potential boost by subsequent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in the United Kingdom (UK).

12 Sep 2022

Long-COVID in adults and Ontario's expected burden

Scientists identify the healthcare requirements for adults with long COVID.

12 Sep 2022

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

Researchers provided a summary of SARS-CoV-2 infections among children pre- and post-SARS-CoV-2 Delta and Omicron variants of concern (VOCs) emergence.

12 Sep 2022

Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz.

12 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

In a recent study posted to the bioRxiv* preprint server, researchers in Germany and the United Kingdom investigated the interferon responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant and SARS-CoV-2 Omicron sub-variants BA.1 and BA.5, and their efficacy in protecting cells from influenza A virus super-infection.

12 Sep 2022

Self-replicating intradermal RNA vaccine against SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, researchers assessed the efficiency of a controllable self-replicating ribonucleic acid (c-srRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 Sep 2022

Antibody escape less pronounced with BA.2.75 compared to BA.4/5

In a recent study published in the Lancet, researchers evaluated the antibody neutralization sensitivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2.75 subvariant.

11 Sep 2022

Discovery of antibodies that may eliminate the need for COVID vaccines

...

11 Sep 2022

Individual COVID-19 infections include multiple variants of the SARS-CoV-2 virus, research shows

Researchers at Case Western Reserve University found wide genetic variation in SARS-CoV-2 viruses among 360 patients whose viral infections were genetically sequenced, showing that all individual infections include multiple variants of the virus.

9 Sep 2022

All SARS-CoV-2 variants neutralized by a potent new antibody

Researchers describe a mouse model used to generate a VH1-2 heavy chain (HC)- and Vκ1-33 light chain (LC)-based recombinant antibody that broadly neutralized all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the newly emergent Omicron sub-variant BA.5.

9 Sep 2022

Promising anti-cancer agent may also prevent SARS-CoV-2 from replication

Based on findings from a new study by a Johns Hopkins Medicine-led research team, an effective means of fighting SARS-CoV-2, the virus that causes COVID-19, may be possible that circumvents the problem of waning immunity often observed when current vaccines deal with emerging COVID variants.

8 Sep 2022

Omicron News and Research

What is the effect of the Omicron variant on olfaction?

COVID-19's future is uncertain as infections increase and tracking decreases

High levels of mucosal antibodies in the airways reduce the risk of omicron infection

Customized bivalent mRNA COVID boosters protect against BA.5 Omicron variant

COVID-19 risk substantially reduced in seniors who receive 4th mRNA booster

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

Forecasting COVID-19 surges based on SARS-CoV-2 mutation surveillance

SARS-CoV-2 breakthrough infection in vaccinated individuals induces virus-specific nasal T cells of broad specificity

Vaccines that induce mucosal immunity against SARS-CoV-2 are needed

Long-COVID in adults and Ontario's expected burden

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

Did the US jump the gun with the new omicron-targeted vaccines?

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

Self-replicating intradermal RNA vaccine against SARS-CoV-2

Antibody escape less pronounced with BA.2.75 compared to BA.4/5

Discovery of antibodies that may eliminate the need for COVID vaccines

Individual COVID-19 infections include multiple variants of the SARS-CoV-2 virus, research shows

All SARS-CoV-2 variants neutralized by a potent new antibody

Promising anti-cancer agent may also prevent SARS-CoV-2 from replication

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News